PDF(Pubmed)
Abstract：
UNASSIGNED: By utilizing machine learning, we can identify genes that are associated with recurrence, invasion, and tumor stemness, thus uncovering new therapeutic targets.
UNASSIGNED: To begin, we obtained a gene set related to recurrence and invasion from the GEO database, a comprehensive gene expression database. We then employed the Weighted Gene Co-expression Network Analysis (WGCNA) to identify core gene modules and perform functional enrichment analysis on them. Next, we utilized the random forest and random survival forest algorithms to calculate the genes within the key modules, resulting in the identification of three crucial genes. Subsequently, one of these key genes was selected for prognosis analysis and potential drug screening using the Kaplan-Meier tool. Finally, in order to examine the role of CDC20 in lung adenocarcinoma (LUAD), we conducted a variety of in vitro and in vivo experiments, including wound healing assay, colony formation assays, Transwell migration assays, flow cytometric cell cycle analysis, western blotting, and a mouse tumor model experiment.
UNASSIGNED: First, we collected a total of 279 samples from two datasets, GSE166722 and GSE31210, to identify 91 differentially expressed genes associated with recurrence, invasion, and stemness in lung adenocarcinoma. Functional enrichment analysis revealed that these key gene clusters were primarily involved in microtubule binding, spindle, chromosomal region, organelle fission, and nuclear division. Next, using machine learning, we identified and validated three hub genes (CDC45, CDC20, TPX2), with CDC20 showing the highest correlation with tumor stemness and limited previous research. Furthermore, we found a close association between CDC20 and clinical pathological features, poor overall survival (OS), progression-free interval (PFI), progression-free survival (PFS), and adverse prognosis in lung adenocarcinoma patients. Lastly, our functional research demonstrated that knocking down CDC20 could inhibit cancer cell migration, invasion, proliferation, cell cycle progression, and tumor growth possibly through the MAPK signaling pathway.
UNASSIGNED: CDC20 has emerged as a novel biomarker for monitoring treatment response, recurrence, and disease progression in patients with lung adenocarcinoma. Due to its significance, further research studying CDC20 as a potential therapeutic target is warranted. Investigating the role of CDC20 could lead to valuable insights for developing new treatments and improving patient outcomes.
UNASSIGNED: To begin, we obtained a gene set related to recurrence and invasion from the GEO database, a comprehensive gene expression database. We then employed the Weighted Gene Co-expression Network Analysis (WGCNA) to identify core gene modules and perform functional enrichment analysis on them. Next, we utilized the random forest and random survival forest algorithms to calculate the genes within the key modules, resulting in the identification of three crucial genes. Subsequently, one of these key genes was selected for prognosis analysis and potential drug screening using the Kaplan-Meier tool. Finally, in order to examine the role of CDC20 in lung adenocarcinoma (LUAD), we conducted a variety of in vitro and in vivo experiments, including wound healing assay, colony formation assays, Transwell migration assays, flow cytometric cell cycle analysis, western blotting, and a mouse tumor model experiment.
UNASSIGNED: First, we collected a total of 279 samples from two datasets, GSE166722 and GSE31210, to identify 91 differentially expressed genes associated with recurrence, invasion, and stemness in lung adenocarcinoma. Functional enrichment analysis revealed that these key gene clusters were primarily involved in microtubule binding, spindle, chromosomal region, organelle fission, and nuclear division. Next, using machine learning, we identified and validated three hub genes (CDC45, CDC20, TPX2), with CDC20 showing the highest correlation with tumor stemness and limited previous research. Furthermore, we found a close association between CDC20 and clinical pathological features, poor overall survival (OS), progression-free interval (PFI), progression-free survival (PFS), and adverse prognosis in lung adenocarcinoma patients. Lastly, our functional research demonstrated that knocking down CDC20 could inhibit cancer cell migration, invasion, proliferation, cell cycle progression, and tumor growth possibly through the MAPK signaling pathway.
UNASSIGNED: CDC20 has emerged as a novel biomarker for monitoring treatment response, recurrence, and disease progression in patients with lung adenocarcinoma. Due to its significance, further research studying CDC20 as a potential therapeutic target is warranted. Investigating the role of CDC20 could lead to valuable insights for developing new treatments and improving patient outcomes.
摘要：
■通过利用机器学习，我们可以识别与复发相关的基因，入侵,和肿瘤干性，从而发现新的治疗靶点。
■首先，我们从GEO数据库中获得了与复发和侵袭相关的基因集，一个全面的基因表达数据库。然后我们采用加权基因共表达网络分析(WGCNA)来鉴定核心基因模块并对其进行功能富集分析。接下来,我们利用随机森林和随机生存森林算法来计算关键模块内的基因，从而鉴定出三个关键基因。随后，使用Kaplan-Meier工具选择这些关键基因之一进行预后分析和潜在药物筛选.最后,为了检查CDC20在肺腺癌（LUAD）中的作用，我们进行了各种体外和体内实验，包括伤口愈合试验，集落形成试验,Transwell迁移分析，流式细胞术细胞周期分析，西方印迹,和小鼠肿瘤模型实验。
■首先，我们从两个数据集中总共收集了279个样本，GSE166722和GSE31210，鉴定91个与复发相关的差异表达基因，入侵,肺腺癌的干性。功能富集分析表明，这些关键基因簇主要参与微管结合，主轴,染色体区域，细胞器裂变,核分裂。接下来,使用机器学习，我们鉴定并验证了三个hub基因(CDC45，CDC20，TPX2)，CDC20与肿瘤干性的相关性最高，既往研究有限。此外，我们发现CDC20与临床病理特征密切相关，总体生存率（OS）较差，无进展间隔（PFI），无进展生存期（PFS），肺腺癌患者的不良预后。最后,我们的功能研究表明，敲低CDC20可以抑制癌细胞的迁移，入侵,扩散,细胞周期进程，和肿瘤的生长可能通过MAPK信号通路。
■CDC20已成为监测治疗反应的新型生物标志物，复发,和肺腺癌患者的疾病进展。由于其重要性,需要进一步研究CDC20作为潜在的治疗靶点.研究CDC20的作用可以为开发新的治疗方法和改善患者预后提供有价值的见解。
■首先，我们从GEO数据库中获得了与复发和侵袭相关的基因集，一个全面的基因表达数据库。然后我们采用加权基因共表达网络分析(WGCNA)来鉴定核心基因模块并对其进行功能富集分析。接下来,我们利用随机森林和随机生存森林算法来计算关键模块内的基因，从而鉴定出三个关键基因。随后，使用Kaplan-Meier工具选择这些关键基因之一进行预后分析和潜在药物筛选.最后,为了检查CDC20在肺腺癌（LUAD）中的作用，我们进行了各种体外和体内实验，包括伤口愈合试验，集落形成试验,Transwell迁移分析，流式细胞术细胞周期分析，西方印迹,和小鼠肿瘤模型实验。
■首先，我们从两个数据集中总共收集了279个样本，GSE166722和GSE31210，鉴定91个与复发相关的差异表达基因，入侵,肺腺癌的干性。功能富集分析表明，这些关键基因簇主要参与微管结合，主轴,染色体区域，细胞器裂变,核分裂。接下来,使用机器学习，我们鉴定并验证了三个hub基因(CDC45，CDC20，TPX2)，CDC20与肿瘤干性的相关性最高，既往研究有限。此外，我们发现CDC20与临床病理特征密切相关，总体生存率（OS）较差，无进展间隔（PFI），无进展生存期（PFS），肺腺癌患者的不良预后。最后,我们的功能研究表明，敲低CDC20可以抑制癌细胞的迁移，入侵,扩散,细胞周期进程，和肿瘤的生长可能通过MAPK信号通路。
■CDC20已成为监测治疗反应的新型生物标志物，复发,和肺腺癌患者的疾病进展。由于其重要性,需要进一步研究CDC20作为潜在的治疗靶点.研究CDC20的作用可以为开发新的治疗方法和改善患者预后提供有价值的见解。
